A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.

Cerebrospinal Fluid Leak Clinical Trial

— NEOART  

Official title:

A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes- NEOART Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04145544
• Other study ID #: ARTIFASCIA® DURAL REPAIR PATCH
• Status: Completed
• Phase: N/A
• Start date: January 7, 2020
• Est. completion date: November 1, 2022

Study information

• Verified date: October 2022
• Source: Nurami Medical Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and effectiveness of ArtiFascia® in comparison with commercially available dural substitutes in patients requiring Dural repair following neurosurgery.

Patients with planned cranial neurosurgery can take part in this study. During the surgery the soft membrane that covers the brain (called dura) is likely to be cut and damaged. A damaged dura can cause a leakage of brain fluids (cerebrospinal fluid [CSF] leakage) and increase the risk of infections. Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a medical synthetic dural substitute that is absorbed by the body. ArtiFascia® supports the re-formation of a new dura. In addition it has a sealant layer that can reduce CSF leakage and infection.

Description:

A Prospective, randomized, controlled multi-center study of ArtiFascia® Dural repair patch compared with commercially available dural substitutes- NEOART Study.

The dura mater is a fibrous connective tissue that surrounds the nervous system (brain and spinal cord) and provides a mechanical barrier that contains the cerebrospinal fluid (CSF). The dura mater may be damaged as a result of trauma or planned surgery. When dural defects cannot be repaired by primary closure, a dural substitute must be utilized in order to reduce CSF leakage.

There are devices that have been used as dural substitutes. Among the devices that are based on natural raw materials, collagen-based matrices are widely used. Although collagen was proven to be biocompatible, using collagen-based materials still possess several limitations such as CSF leaks. Synthetic dural substitutes are also used to repair dura mater. The most widely used raw-material for these synthetic products are polyesters - resorbable and biocompatible polymers. There are several dural substitutes based on synthetic polyesters that were successfully tested pre-clinically as well as in human studies.

Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a medical synthetic dural substitute that is absorbed by the body.

Before the study, the patients will have their blood taken and they will undergo neurological assessment. If they are suitable to participate in the study, and agree to participate, they will be randomly allocated into one of the following groups:

• Experimental group (ArtiFascia® device);

• Control group (Other commercially available suturable dural substitutes).

The patients will undergo a surgery that is identical to the one that was planned by the surgeon. At the end of the surgery, the investigator will use ArtiFascia® patch or standard dural substitute to repair the damaged Dura. ArtiFascia® graft will be placed in areas where the native dural layer was damaged or missing. ArtiFascia® will be applied via a routine and well-known procedure, using a suturing technique. After implantation, the porous fibrous structure of ArtiFascia® provides a scaffold, which enables infiltration of fibroblasts and cells from the intact tissue, ultimately replacing damaged dural tissue. The patch is expected to resorb within a few months and to be replaced by the native tissue with complete dural closure.

During the surgery and until patient's release from the hospital the patient's health will be closely monitored. Before the discharge patients will have to undergo neurological examination. Patients will be obligated to attend the follow up visits after the surgery at the dates scheduled by the attending physician.

At each of the visits physical and neurological examinations will be performed. Radiographic Evaluation (Magnetic Resonance Imaging) will be performed also 6 months post operation.

A total of 90 patients will be enrolled and implanted with test or control device. Up to 10 centers in Europe and Israel are planned to participate in this study.

The primary endpoint will be achieved when the final study subject has completed a 6-months follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: November 1, 2022
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subject between the ages of 18-75

2. Subject is scheduled for an elective cranial surgery with a dural damage that can be completely repaired/closed by a suture-able dural substitute (ArtiFascia device or other commercially available dural substitutes)

3. Subject has undergone radiographic imaging (such as, MRI) in the past 6 months before enrolment

4. Surgical wound is expected to be Class I/clean

5. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

6. Subject is able and willing to adhere to the required follow-up visits and testing

Exclusion Criteria:

1. Pregnant women or interest in becoming pregnant during the duration of the study

2. Subject has known hydrocephalus

3. Subject is unable to undergo MRI after the surgery

4. Subject's life expectancy is less than 12 months

5. Subject has a local or systemic infection (e.g. urinary tract infection (UTI), active pneumonia) or evidence of any surgical site infection, fever > 38.3?, positive blood culture and/or a positive chest x-ray for acute infectious process

6. Subject will require use of dural adhesive or sealant

7. Subject is intended to undergo craniectomy wherein bone flap will not be returned

8. Subject with suspected low success in wound healing due to past treatments (e.g. chemotherapy, radiation therapy, severe diabetes etc.) or other conditions (e.g. severe peripheral vascular disease, long standing steroids treatment)

9. Subject has been clinically diagnosed with malignancy (other than basal cell carcinoma or low-grade glioma), uncontrolled diabetes (A1C>6.5%), sepsis, systemic collagen disease.

10. Subject had chemotherapy and/or radiotherapy in the past 12 weeks before surgery or is planned to have chemotherapy or radiotherapy less than 12 weeks after surgery.

11. Subject is an acute cranial trauma surgical case

12. Subjects with a concurrent disease that would place the patient in excessive risk to the planned surgery

13. Subject had a previous neurosurgery in the same anatomical site

14. Subject with other undesirable symptoms defined by the principal investigator

15. Patient has clinically significant coagulopathy as determined by the surgeon

16. Subject is participating in another clinical trial using similar investigational devices/drugs

Related Conditions & MeSH terms

• Cerebrospinal Fluid Leak
• Dural Tear

Intervention

Device:
• Implantation of the ArtiFascia®
Following are the general instructions for use for the ArtiFascia®: Cut the ArtiFascia® to the required shape under aseptic conditions Apply ArtiFascia® to the damaged area Suture the ArtiFascia® in place Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision. Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.
• Implantation of other commercial suturable dural substitute
Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use

Locations

Country	Name	City	State
Belgium	Ziekenhuis Oost-Limburg	Genk
Czechia	St. Anne's University Hospital Brno	Brno
Czechia	Neurochirurgická klinika Prednosta FN Olomouc	Olomouc
Israel	Rabin Medical Center (Beilinson, Hasharon)	Petah Tikva
Poland	Medical University of Gdansk	Gdansk
Poland	Barlicki University Hospital	Lódz
Spain	Hospital Clinic de Barcelona	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Universitario de Bellvitge	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Nurami Medical Ltd

Countries where clinical trial is conducted

Belgium,  Czechia,  Israel,  Poland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the safety and effectiveness of ArtiFascia® in comparison with commercially available suturable dural substitutes in subjects requiring Dural repair following neurosurgery	Safety and effectiveness will be assessed by evaluating the absence of CSF fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging. During MRI imaging CSF leakage will be assessed as: none/external leakage/subgaleal leakage. Additional if leakage is present, severity will be reported (mild/moderate/severe).	The rate of adverse events, adverse device effects and device deficiencies will be assessed on a continuous basis from the baseline (following signing the ICF) through the study completion at 6 month.
Secondary	Wound healing assessment	Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.	6 month follow-up
Secondary	Device Handling Characteristics	Based on scale to evaluate device: Suturing, seal quality, strength, ease of use (Score from 1=easy to 5=difficult).	6 month follow-up
Secondary	Radiographic evaluation (Magnetic Resonance Imaging).	To determine the presence or absence of the following measure: adhesion formation, new tissue formation, pseudomeningocele, extracerebal fluid collection and brain edema adjacent to device implant size Measurements will be done based on MRI imaging (X,Y,Z axis; in milimeters).	6 month follow-up